Contemporary outcomes of precision banding for high flow hemodialysis access
The Journal of Vascular Access · 2023-11 · 24 (6) · 1260-1267
DOI: 10.1177/11297298221076581 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Vascular Access, online erschienen am 09.02.2022. Verfasst von Andrew J Soo Hoo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Arteriovenous Shunt, Surgical, Thrombosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Objective
High-flow hemodialysis accesses are a well-recognized source of patient morbidity. Among available management strategies inflow constriction based on real-time physiologic flow monitoring offers a technically straightforward data-driven approach with potentially low morbidity. Despite the benefits offered by this approach, large contemporary series are lacking.
Methods
A retrospective review of a prospectively maintained clinical database was undertaken to capture patients undergoing precision banding within a signal tertiary care institution between 2010 and 2019. Multivariable logistic regression modeling of thrombosis within 30 days and re-banding within 1 year were performed.
Results
In total, 297 patients underwent banding during the study period for a total number of 398 encounters. Median [IQR] follow-up was 157 [52–373] days. Most accesses were upper arm with brachial artery inflow (84%) and half of the banding procedures were performed for flow imbalance based on exam, duplex, or fistulogram. Median flow rate reduction was 58%. The 30-day thrombosis rate after banding was 15 of 397 (3.8%) with a median time to event of 5.5 days (2–102). The re-banding rate within a year was 54 of 398 (14%) with a median time to re-banding of 134 days [56–224]. Multivariate logistic regression analysis using a univariate screen did not identify any predictors of 30-day thrombosis. Having a forearm radial-cephalic AVF compared to all other access types was protective against need for rebanding at 1 year (OR 0.12 95% CI 0.02–0.92, p = 0.04), as was flow imbalance as the indication for banding (OR 0.43 95% 0.23-0.79, p = 0.006).
Conclusions
Precision banding offers an effective, low-morbidity approach for high-flow hemodialysis accesses. Early thrombosis is a rare event after precision banding, although in the long term, one in four patients will require re-banding to maintain control of flow volumes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Boston, MA, USA.
- Kaiser Permanente Santa Clara Medical Center, Santa Clara, CA, USA.
- Capital Health Vascular Group, Patterson, NJ, USA.
- Interventional Nephrology, Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA, USA.
ORCID-Profile: Rebecca E Scully, Adina Voiculescu, Dirk M Hentschel
Zitieren
APA
Soo Hoo, A. J., Scully, R. E., Sharma, G., Patterson, S., Walsh, J., Voiculescu, A., Belkin, M., Menard, M., Keith Ozaki, C., & Hentschel, D. M. (2023). Contemporary outcomes of precision banding for high flow hemodialysis access. The Journal of Vascular Access, 24(6), 1260-1267. https://doi.org/10.1177/11297298221076581
Vancouver
Soo Hoo AJ, Scully RE, Sharma G, Patterson S, Walsh J, Voiculescu A, et al. Contemporary outcomes of precision banding for high flow hemodialysis access. The Journal of Vascular Access. 2023;24(6):1260-1267. doi:10.1177/11297298221076581
BibTeX
@article{SooHoo2023,
author = {Soo Hoo, Andrew J and Scully, Rebecca E and Sharma, Gaurav and Patterson, Suzannah and Walsh, Jillian and Voiculescu, Adina and Belkin, Michael and Menard, Matthew and Keith Ozaki, C and Hentschel, Dirk M},
title = {Contemporary outcomes of precision banding for high flow hemodialysis access},
journal = {The Journal of Vascular Access},
year = {2023},
volume = {24},
number = {6},
pages = {1260--1267},
doi = {10.1177/11297298221076581}
}
EUVIMED